PERSPECTA

News from every angle

Back to headlines

Neurocrine to Acquire Soleno in $2.9 Billion Transaction

Neurocrine Biosciences has announced its intention to acquire Soleno Therapeutics in a transaction valued at $2.9 billion.

PostShare

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.